Skip to content

US · RAPP · BIOTECHNOLOGY

Rapport Therapeutics, Inc. Common Stock (RAPP) intrinsic value and stock valuation

$23.16as of 2026-11-21 · Mkt cap 2.18B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Rapport Therapeutics, Inc. Common Stock DCF and intrinsic value

InvestorsCraft values RAPP with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from RAPP’s statements →

Rapport Therapeutics, Inc. Common Stock Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Boston, MA 02110 rapportrx.com

How the business is doing

Fiscal 2022–2025, USD

Revenue
$0.00
20222025
Net income
-$-111.48M
20222025
Free cash flow
-$-88.09M
20222025
Total equity
$484.7M
20222025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2022–2025, USD
2025202420232022
Revenue$0.00$0.00$0.00$0.00
Operating income-$-125.1M-$-83.06M-$-36.18M-$-10.37M
Net income-$-111.48M-$-78.31M-$-34.79M-$-10.65M
EPSd-$-2.37M-$-3.78M-$-1.92M-$-529.32K
Operating cash flow-$-87.47M-$-64.83M-$-27.18M-$-3.24M
Capital expenditure-$-620K-$-2.4M-$-1.64M-$-280K
Free cash flow-$-88.09M-$-67.23M-$-28.82M-$-3.53M
Total assets$512.4M$314.9M$155.4M$31.6M
Total debt$11.5M$1.48M$2.15M$10.4M
Net debt-$-41.16M-$-55.33M-$-68.02M-$-20.72M
Total equity$484.7M$305.4M-$-25.63M$19.5M
Cash and short-term investments$490.5M$305.3M$147.5M$31.2M
Income statement
2025202420232022
Revenue$0.00$0.00$0.00$0.00
Cost of revenue$1.02M$840K$110K$10K
Gross profit-$-1.02M-$-840K-$-110K-$-10K
Research and development expenses$94.8M$60.9M$28M$9.12M
Selling, general and administrative expenses$30.3M$22.1M$8.07M$1.37M
Other expenses$0.00-$-840K$0.00-$-130K
Operating expenses$125.1M$82.2M$36.1M$10.4M
Cost and expenses$125.1M$83.1M$36.2M$10.4M
Interest income$13.6M$12.1M$2.53M$0.00
Interest expense$0.00$0.00$0.00$280K
Depreciation and amortization$1.02M$840K$110K$10K
Ebitda-$-124.08M-$-77.47M-$-34.66M-$-10.35M
Operating income-$-125.1M-$-83.06M-$-36.18M-$-10.37M
Total other income/expenses, net$13.6M$4.75M$1.4M-$-280K
Income before tax-$-111.48M-$-78.31M-$-34.78M-$-10.65M
Income tax expense$0.00$0.00$10K$0.00
Net income-$-111.48M-$-78.31M-$-34.79M-$-10.65M
Weighted average shares outstanding$47M$20.7M$18.1M$20.1M
Weighted average diluted shares outstanding$47M$20.7M$18.1M$20.1M
Balance sheet
2025202420232022
Cash and short-term investments$490.5M$305.3M$147.5M$31.2M
Net receivables$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00
Total current assets$498.6M$309.8M$150.9M$31.3M
Property, plant and equipment, net$12.9M$4.97M$4M$340K
Goodwill and intangible assets$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00
Total non-current assets$13.9M$5.13M$4.55M$340K
Total assets$512.4M$314.9M$155.4M$31.6M
Accounts payable$4.19M$1.95M$2.5M$1.45M
Short-term debt$2.75M$740K$670K$0.00
Deferred revenue$0.00$0.00$0.00$0.00
Total current liabilities$19.1M$8.77M$8.8M$1.66M
Long-term debt$8.73M$740K$1.48M$10.4M
Deferred revenue, non-current$0.00$0.00$0.00$0.00
Total non-current liabilities$8.73M$740K$172.3M$10.4M
Capital lease obligations$2.75M$1.48M$2.15M$0.00
Total liabilities$27.8M$9.51M$181.1M$12.1M
Common stock$50K$40K$0.00$30K
Retained earnings-$-235.23M-$-123.75M-$-45.44M-$-10.65M
Accumulated other comprehensive income (loss)$550K-$-520K$0.00$0.00
Total equity$484.7M$305.4M-$-25.63M$19.5M
Total investments$437.9M$248.5M$77.3M$0.00
Total debt$11.5M$1.48M$2.15M$10.4M
Net debt-$-41.16M-$-55.33M-$-68.02M-$-20.72M
Cash flow statement
2025202420232022
Net income-$-111.48M-$-78.31M-$-34.79M-$-10.65M
Depreciation and amortization$1.02M$840K$110K$20K
Stock-based compensation$18.9M$10.2M$3.52M$610K
Change in working capital$3.5M-$-2.42M$2.65M$1.49M
Accounts receivable$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00
Accounts payable$2.21M-$-350K$860K$0.00
Net cash provided by operating activities-$-87.47M-$-64.83M-$-27.18M-$-3.24M
Investments in property, plant and equipment-$-620K-$-2.4M-$-1.64M-$-280K
Acquisitions, net$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-187.47M-$-170.14M-$-78.86M-$-5.28M
Common stock issued$270.8M$157.7M$50K$31.8M
Common stock repurchased-$0.00$0.00-$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00
Net cash used for financing activities$270.8M$221.6M$145.1M$39.7M
Net change in cash-$-4.16M-$-13.34M$39.1M$31.2M
Cash at end of period$52.8M$56.9M$70.3M$31.2M
Operating cash flow-$-87.47M-$-64.83M-$-27.18M-$-3.24M
Capital expenditure-$-620K-$-2.4M-$-1.64M-$-280K
Free cash flow-$-88.09M-$-67.23M-$-28.82M-$-3.53M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Rapport Therapeutics, Inc. Common Stock

        Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.

        CEO
        Abraham N. Ceesay
        Employees
        84
        Beta
        0.95

        Explore

        Frequently asked questions

        What is the intrinsic value of Rapport Therapeutics, Inc. Common Stock (RAPP)?

        InvestorsCraft does not currently publish an intrinsic value for RAPP. How the IC value is calculated.

        Is RAPP undervalued?

        InvestorsCraft does not publish an undervaluation signal for RAPP at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.